 The Deal Pipeline | Abbott continues to prep for new focus The Deal Pipeline It has also supplemented its pipeline through additional partnerships over the past few years, forging deals with Reata, Biogen Idec Inc. (daclizumab for multiple sclerosis) and Bristol-Myers Squibb Co. with its MS drug elotuzumab. |
